SAFE SUPPLY AND ORIGIN THERAPEUTICS RECEIVE CONDITIONAL APPROVAL FOR LISTING ON THE CSE
September 11, 2023 20:00 ET
|
Origin Therapeutics Holdings Inc.
VANCOUVER, BC, CANADA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Safe Supply Streaming Co. Ltd. (“Safe Supply” or the “Company”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to...
Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
September 05, 2023 15:57 ET
|
Origin Therapeutics Holdings Inc.
VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (the “Company” or “Origin”) (CSE: ORIG) is pleased to announce that, in connection with the proposed...
SAFE SUPPLY AND ORIGIN THERAPEUTICS ANNOUNCE SIGNING OF DEFINITIVE AGREEMENT
August 02, 2023 12:01 ET
|
Origin Therapeutics Holdings Inc.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC, CANADA,...
Origin Therapeutics Announces Closing of Safe Supply Subscription Receipt Financing
August 02, 2023 11:58 ET
|
Origin Therapeutics Holdings Inc.
Vancouver, British Columbia, Canada, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (“Origin” or the “Company”) is pleased to announce the closing of a private placement...
SAFE SUPPLY AND ORIGIN THERAPEUTICS ANNOUNCES ENGAGEMENT OF RESEARCH CAPITAL AND UPSIZING OF BROKERED FINANCING TO $4 MILLION
March 02, 2023 13:21 ET
|
Origin Therapeutics Holdings Inc.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC, CANADA,...
Origin Enters into Binding Letter of Intent with Safe Supply Streaming Co., a Pharmaceutical and Narcotics Investment Company with a First Mover Advantage in the Safe Supply Narcotics Sector
January 31, 2023 15:35 ET
|
Origin Therapeutics Holdings Inc.
Vancouver, B.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- The completion of the transaction is anticipated to create the world’s first publicly-listed pharmaceutical and narcotics investment company...
Origin Therapeutics Announces New Director
October 31, 2022 19:00 ET
|
Origin Therapeutics Holdings Inc.
Vancouver, B.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE:ORIG) (the “Company” or “Origin Therapeutics”), announces the election of Jonathan Goldman as a new director...
Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland
October 18, 2022 18:00 ET
|
Origin Therapeutics Holdings Inc.
Vancouver, BC , Oct. 18, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE: ORIG) (the “Company”, “Origin Therapeutics” or “Origin”), an actively managed, psychedelics industry-focused...
Origin Therapeutics Announces Director Resignation
October 03, 2022 23:59 ET
|
Origin Therapeutics Holdings Inc.
Vancouver, B.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE:ORIG) (the “Company” or “Origin Therapeutics”) announces that Michael Young has resigned as a director of...
Origin Therapeutics’ Portfolio Company, Xpira Pharmaceuticals, Receives FDA Approval For Psilocybin Trial IND Application
September 22, 2022 11:42 ET
|
Origin Therapeutics Holdings Inc.
Toronto, ON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE: ORIG) (the “Company” or “Origin Therapeutics”), an actively managed, psychedelics industry-focused investment...